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ABSTRACT
Background    We investigated the distinguishing 
pathological features of bilateral ovarian tumors using 
magnetic resonance (MR) imaging.
Methods    Eighty-six patients with bilateral ovarian 
tumors on MR imaging were evaluated. The patholog-
ical diagnosis was investigated, and the results were 
subjected to statistical analysis using Mann-Whitney U 
test, Fisher’s exact test, Chi-squared test and receiver 
operating characteristic (ROC) curve to determine the 
features useful for the differentiation of distinct types of 
lesions.
Results    The diagnosis of bilateral ovarian tumors was 
confirmed in eighty-one patients and the majority of the 
lesions were further classified into serous carcinoma 
(n = 36), mature teratoma (n = 20) and metastasis (n = 
12). We assessed the existence of factors useful for the 
MR imaging differentiation between metastasis and 
serous carcinoma or primary malignant ovarian tumors. 
Cancer antigen (CA) 125 serum level and maximum 
tumor diameter were significantly different between 
metastasis and serous carcinoma and similarly, between 
metastasis and primary malignant ovarian tumors. MR 
imaging morphology, ascites and peritoneal implants did 
not show any significant difference between the different 
types of lesions. 
Conclusion    Within our patient cohort, most bilateral 
ovarian tumor lesions were determined to be serous car-
cinoma, mature teratoma or metastasis. CA 125 serum 
level and maximum tumor diameter are useful markers 
for the differentiation between metastasis and serous 
carcinoma or primary malignant ovarian tumors.
Key words    bilateral; cancer antigen 125; magnetic 
resonance imaging; maximum tumor diameter; ovarian 
tumor
Ovarian tumors are commonly occurring gynecological 
disorders. Among these, ovarian cancer is the seventh 
most common form of cancer in women globally.1 
On the other hand, 5% to 10% of malignant tumors 
involving the ovaries are metastasis.2 The preoperative 
differentiation between metastasis and primary ovarian 
tumors is important in selecting the most appropriate 
treatment.3 However, the diagnosis is sometimes chal-
lenging, because metastatic ovarian tumors are some-
times detected before the primary tumor is diagnosed.
 Most studies have reported that the differentiation 
between primary and metastatic ovarian tumors, in-
cluding Krukenberg tumors, was often not made preop-
eratively, due to their very similar appearance.3–5 Some 
studies reported that metastatic ovarian tumors were 
usually bilateral,5, 6 and the bilaterality was a useful 
feature to differentiate primary from metastatic ovarian 
tumors.4, 7 However, other authors reported differently.3, 
8 Some common primary tumors such as serous and 
undifferentiated carcinomas are also known to involve 
bilateral ovaries in a high proportion of cases.2 In reality, 
bilateral primary ovarian tumors are sometimes encoun-
tered in daily practice on magnetic resonance (MR) im-
aging examination. These conflicting reports demanded 
further investigations on the distinguishing pathological 
and morphological features of bilateral ovarian tumors. 
On the other hand, there are no sufficient data about the 
way to differentiate the bilateral ovarian tumors detected 
on MR imaging. The aim of this study is thus to inves-
tigate the distinct pathological types of bilateral ovarian 
tumors detected on MR imaging, and to determine 
the existence of useful markers for the differentiation 
between the distinct types of bilateral ovarian tumors, 
including primary ovarian tumors and metastasis.
MATERIALS AND METHODS
Patient Population
In this retrospective study, 457 consecutive patients 
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presenting ovarian tumors on MR imaging examination 
were included. They were all pathologically diagnosed. 
These patients underwent MR examinations between 
January 2005 and March 2015. Endometriotic cysts 
and functional cysts were excluded on MR findings and 
ultrasound examination for follow-up. Of the patients 
presenting ovarian tumor lesions, 371 patients were 
excluded due to unilateral tumor on MR imaging. A 
total of 86 patients were enrolled. Approval by the ethics 
committee of Tottori University was obtained for the 
study, and the requirement for informed consent was 
waived (1606A027).
MR Imaging Technique
MR imaging was performed using three 3.0-T MR sys-
tems (Signa EXCITE HD or Discovery MR750w; GE 
Medical Systems, Milwaukee, WI, or Skyra; Siemens 
Health Care, Erlangen, Germany) and two 1.5-T MR 
systems (Achieva; Philips Medical Systems, Best, 
Netherlands or Symphony; Siemens Health Care), with 
phased array coils. 
 Axial and sagittal T1-weighted images, and axial 
and sagittal T2-weighted images were obtained in all 
patient cases. Scan parameters and sequences varied be-
cause the study was conducted over a period of 10 years. 
Representative pelvic MR images were acquired using 
the following sequences and scan parameters: axial and 
sagittal T1-weighted spoiled gradient recalled (SPGR) 
images [repetition time (TR), 250 ms; echo time (TE), 
2.1 ms; flip angle (FA), 75°; acquisition time, 1 min 30 s], 
axial and sagittal T2-weighted fast SE images (TR, 6500 
ms; TE, 100 ms; section thickness, 5 mm; intersection 
gap, 1.5 mm; acquisition time, 3–3.5 min), and axial 
and/or sagittal SPGR images with fat suppression (TR, 
320 ms; TE, 2.1 ms; FA, 75°; acquisition time, 1 min 
50 s). Axial diffusion weighted (DW) images were then 
obtained. Imaging parameters for DW imaging were as 
follows: TR, 5500–6000 ms; TE, 60–62 ms; inversion 
time (TI), 200 ms; b factors, 0 and 1000 s/mm2; 112 
× 128 matrix; field of view (FOV), 400 mm; section 
thickness, 4–6 mm with no gap; SENSE reduction 
factor, 2; signals acquired, 4; acquisition time, 3.5 min. 
The DW imaging sequence was used for fat suppression 
in short TI inversion recovery (STIR) -echo planar im-
aging sequence, with free breathing during acquisition. 
Motion-probing gradient pulses were placed in the three 
orthogonal planes. Isotropic DW imaging was generated 
using three orthogonal-axis images. 
 In 73 patient cases, contrast-enhanced MR images 
were obtained. Except for one patient case, dynamic MR 
images were also obtained. Images were acquired before 
and immediately after rapid intravenous injection of 
the contrast agent (0.2 mL/kg of gadolinium injection), 
and then repeated at 25 or 30, 60, 90, and 120 seconds 
during examination.
 Prior to the examination, patients whose images 
were obtained in 3.0T Signa EXCITE HD received in-
tramuscular administration of 20 mg butyl-scopolamine 
(Buscopan; Nippon Boehringer Ingelheim, Tokyo, 
Japan) to prevent peristalsis artifacts, unless contraindi-
cated.
Image Analysis
MR images were independently analyzed by two ra-
diologists (S.F. and N.M., 16 and 5 years of experience 
in gynecological MR imaging, respectively) to evaluate 
the bilaterality of the lesions. Consensus between the 2 
radiologists was reached after careful individual exam-
ination. MR images of patients presenting bilateral ovar-
ian tumors were analyzed by a radiologist (N.M.) on the 
basis of the following findings: i) morphology - predom-
inantly cystic (less than half of solid component) or pre-
dominantly solid (more than half of solid component); ii) 
maximum tumor diameter - calculated by summing the 
bilateral of each maximum tumor diameter. When bilat-
eral tumors were fused, the maximum diameter of the 
fused mass was measured; iii) ascites - none, not beyond 
the pelvic cavity or beyond the pelvic cavity; and iv) 
peritoneal implants. The reader was blinded to the clini-
cal patient data and pathological reports. The solid com-
ponent included thickened septa, vegetation (papillary 
projection) and solid portions showing enhancement on 
contrast-enhanced T1-weighted imaging. Morphology, 
ascites and peritoneal implants were identified on these 
images including DW imaging.
Statistical Analysis
All statistical analyses were performed for comparison 
between serous carcinoma and metastasis, and between 
primary malignant ovarian tumors and metastasis. The 
differences in morphology and peritoneal implants were 
compared using Fisher’s exact test and Chi-squared 
test. Maximum tumor diameter, ascites and CA 125 
serum levels were analyzed using Mann-Whitney test. 
CA 125 serum levels were not available for two of the 
patients presenting metastatic ovarian tumors. Receiver 
operating characteristic (ROC) curve analysis was 
performed in order to assess diagnostic performance. 
Statistical analyses were performed using SPSS version 
21.0 for windows (SPSS, Chicago, IL). By maximizing 
the Youden index (defined as sensitivity plus specificity 
minus 1), we determined the optimal cutoff values and 
corresponding sensitivity and specificity values. 
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RESULTS
A total of 86 patients (mean age, 54 years; 
range, 15-86 years) presented bilateral ovar-
ian tumors on MR imaging examination. 
Five of the 86 patients showed patholog-
ically unilateral tumors, though bilateral 
tumors were observed on MR imaging. The 
pathological diagnoses of the remaining 81 
patients are shown in Table 1. In 77 of the 
patient cases, the bilateral tumor lesions 
presented the same pathology on both sides. 
In the 4 remaining patients, the bilateral tu-
mors were pathologically different on each 
side (Fig. 1). Most of the bilateral tumors 
were classified as serous carcinoma (n = 
36), mature teratoma (n = 20) and metasta-
sis (n = 12). The primary site of metastasis 
included appendiceal cancer (mucinous car-
cinoma, n = 2; signet ring cell carcinoma, 
n = 1), colon cancer (n = 2), uterine cervical cancer (n = 
2), bile duct cancer (n = 1), gastric cancer (n = 1), kidney 
cancer (n = 1), peritoneal mesothelioma (n = 1) and 
uterine malignant lymphoma (n = 1) (Figs. 2-4). Mature 
teratomas are not generally problematic for a differential 
diagnosis on MR imaging. Therefore, further investiga-
tions were performed to differentiate serous carcinoma, 
primary malignant ovarian tumors and metastasis. 
Table 1. Pathological diagnosis of bilateral ovarian tu-
mors
Pathological type N 
Primary benign Total 26
Mature teratoma 20
Mature teratoma/Serous adenoma 1
Mature teratoma/Struma ovarii 1
Serous adenoma 3
Fibroma 1
Primary benign and malignant Total 1
Serous adenoma/Mucinous borderline tumor 1
Primary malignant Total 42
Serous carcinoma 36
Clear cell carcinoma 3
Carcinosarcoma 2
Borderline endometrioid tumor/
Endometrioid carcinoma 1
Metastasis Total 12
Appendiceal cancer 3
Cervical cancer 2
Colon cancer 2
Bile duct cancer 1
Gastric cancer 1
Kidney cancer 1
Peritoneal mesothelioma 1
Uterine malignant lymphoma 1
 Results in CA 125, maximum tumor diameter, 
morphology, ascites and peritoneal implants are sum-
marized in Tables 2 and 3. The first analyses aimed to 
differentiate serous carcinoma from metastasis. CA 125 
serum levels in serous carcinomas were significantly 
higher compared to metastasis (P < 0.01, AUC = 0.86, 
sensitivity 72%, specificity 90%, the optimal cutoff val-
ue = 683.3 U/mL), and maximum tumor diameters were 
significantly smaller (P < 0.05, AUC = 0.69, sensitivity 
58%, specificity 83%, the optimal cutoff value = 164 
mm). However, no significant difference was determined 
in morphology (P = 0.32), ascites (P = 0.26) and perito-
neal implants (P = 0.09). When CA 125 was lower than 
the cutoff value or maximum tumor diameter was larger 
than the cutoff value, the sensitivity and specificity of 
metastasis were 90% and 58%. Similar analyses were 
performed to differentiate primary malignant ovarian 
tumors from metastasis. CA 125 levels in primary ma-
lignant ovarian tumors were significantly higher com-
pared to metastasis (P < 0.01, AUC = 0.81, sensitivity 
64%, specificity 90%, the optimal cutoff value = 683.3 
U/mL) and maximum tumor diameters were signifi-
cantly smaller (P < 0.05, AUC = 0.67, sensitivity 58%, 
specificity 81%, the optimal cutoff value = 164 mm). No 
significant difference was determined in morphology 
(P = 0.42), ascites (P = 0.19), or peritoneal implants (P = 
0.24) between the different types of lesions. When CA 
125 was lower than the cutoff value or maximum tumor 
diameter was larger than cutoff value, the sensitivity and 
specificity of metastasis were 90% and 52%.
Bilateral ovarian 
tumors  
in MR imaging (n = 86)	
Bilateral ovarian tumors  
in Pathology (n = 81)	
Excluded 
Unilateral ovarian tumors  
in Pathology (n = 5)	
Same ovarian tumors on both sides 
 (n = 77) 
  　Serous carcinoma (n = 36) 
  　Clear cell carcinoma (n = 3) 
  　Carcinosarcoma (n = 2) 
  　Mature teratoma (n = 20) 
  　Metastasis (n = 12) 
  　Others (n = 4) 
Different ovarian tumors on each side  
(n = 4) 
  　Borderline endometrioid tumor/  
     Endometrioid carcinoma (n = 1) 
  　Others (n = 3)	
TABLE 1	
Fig. 1. Flow diagram of patients presenting bilateral ovarian tumors on MR 
imaging examination. MR, magnetic resonance.
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Fig. 2. Representative case of a 50-year-old female patient presenting serous carcinoma (CA 125 serum level: 5066 U/mL). Bilateral mul-
tilocular cystic ovarian tumors with solid components, massive ascites and peritoneal implants (arrows) in the cul-de-sac are demonstrated 
on T2 weighted image (a) and contrast-enhanced T1 weighted image with fat-suppression (b). Solid components of ovarian tumors and 
peritoneal implants (arrows) show high intensity on DW image (c). CA, cancer antigen; DW, diffusion weighted.
DISCUSSION
Our results demonstrated that most bilateral ovarian 
tumors detected on MR imaging consisted of serous car-
cinoma, mature teratoma and metastasis. These tumors 
should thus be considered as representative bilateral 
ovarian tumors. In 10 to 15% of cases, mature terato-
mas involve both ovaries simultaneously.9–11 Although 
we recognize that mature teratomas sometimes show 
bilateral ovarian tumors, we excluded them for further 
analysis as they can be easily diagnosed by detection of 
fat components and chemical shift artifact.12 In addition, 
most of the primary malignant bilateral ovarian tumors 
were serous carcinomas. The differentiation between 
primary and metastatic ovarian tumors is a clinically 
important issue. Therefore, we first assessed the differ-
entiation between metastasis and serous carcinomas, and 
we then performed a similar analysis for the distinction 
between metastasis and primary malignant ovarian 
tumors. 
 Our results demonstrated that CA 125 serum level 
and maximum tumor diameter were useful parameters 
for the differentiation between metastasis and serous 
carcinoma or primary tumors. CA 125 antigen is a gly-
coprotein with a high molecular weight and is expressed 
by most epithelial ovarian cancers.13, 14 Approximately 
80-85% of ovarian cancer patients present increased CA 
125 serum levels.13, 15 In our study, a CA 125 cutoff value 
of 683.3 U/mL was determined to be a useful marker for 
the differentiation between primary malignant ovarian 
tumors and metastasis. Other authors reported that CA 
Fig. 3. Representative case of a 73-year-old female presenting serous carcinoma (CA 125 serum level: 3532 U/mL). Bilateral solid ovarian 
tumors, massive ascites and peritoneal implants (arrows) in the cul-de-sac are shown on T2 weighted image (a) and contrast-enhanced 
T1 weighted image with fat-suppression (b). Ovarian tumors and peritoneal implants show high intensity on DW image (c). CA, cancer 
antigen; DW, diffusion weighted.
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Table 2. CA 125 and maximum tumor diameter
Mean CA 125
(U/mL)
Mean maxi-
mum tumor 
diameter 
(mm)
Serous carcinoma (N = 36) 3261.0 (103.2–31550) 120 (28–304)
Primary malignant ovarian 
tumor (N = 42) 2834.1 (40.4–31550) 124 (28–304)
Metastasis (N = 12) 389.7 (23.3–1720) 170 (68–360)
(  ) : range
CA, cancer antigen.
125 levels had limited value in the diagnosis between 
primary and metastatic ovarian tumors.15 The reason 
underlying this discrepancy is not clear, but may be re-
lated to tumor extent and bias in histological types. The 
CA 125 serum levels of ovarian cancer patients correlate 
with the FIGO stages.15–17 Bilateral tumors are often 
characteristic of advanced stages. In addition, increased 
CA 125 levels in patients presenting serous carcinoma 
and undifferentiated carcinoma are higher than other 
type of tumors.18 In the present study, the most common 
histological type of primary tumors was serous carci-
nomas. Therefore, markedly high CA 125 levels are 
useful indicators for the prediction of primary malignant 
ovarian tumors.
 Maximum tumor diameter was also useful for 
the differentiation; the maximum diameter of serous 
carcinoma or primary malignant ovarian tumors were 
smaller than metastasis. When CA 125 was lower than 
cutoff value in differentiation between primary ovarian 
tumors and metastasis, or maximum tumor diameter 
was larger than cutoff value, the sensitivity and specific-
ity of metastasis were 90% and 52%. The sensitivity is 
high. Therefore, when these findings are shown, we can 
take metastasis into consideration and suggest further 
examinations. We consider that this strategy is cost ef-
Fig. 4. Representative case of a 57-year-old 
female presenting metastasis from sigmoid 
colon cancer (CA 125 serum level: 651 U/
mL). Bilateral multilocular ovarian cystic 
tumors with thick internal septae (arrows) 
are shown on T2 weighted image (a) and 
contrast-enhanced T1 weighted image with 
fat-suppression (b). CA, cancer antigen.
fective. However, a previous study reported that primary 
ovarian tumors were larger than metastasis.7 The differ-
ent result is considered to be due to the different study 
design and population. We included the cases showing 
bilateral ovarian tumors on MR imaging. On the other 
hand, the previous studies included the cases of ovarian 
carcinomas confirmed by pathology. We consider that 
our inclusion criterion is more practical on the basis of 
clinical daily practice.
 Our results also demonstrated that MR imaging 
findings such as general morphology, ascites and 
peritoneal implants are not useful indicators. These 
results are in agreement with previous studies.19, 20 In 
relation to the morphology, nearly half of the patient 
cases presented  predominant solid patterns in serous 
carcinomas, primary ovarian tumors and metastasis. In 
other words, these tumors presented variable morpholo-
gy. Serous carcinomas are classically known to present 
various and complex appearances including cystic and 
solid components.21, 22 In addition, one possible reason 
behind the variable morphology may be the process to 
serous carcinoma. Serous carcinoma are classified into 
low and high grades. Low grade serous carcinoma (LGSC) 
are considered to develop through a stepwise process 
going from benign serous cystadenomas/adenofibromas 
to serous borderline tumors and ultimately to LGSC.23, 
24 Therefore, LGSC can demonstrate cystic lesions with 
mural nodules.22 In contrast, high grade serous carci-
noma (HGSC) are considered to be de novo promoted 
lesions,23, 24 and are often seen as solid masses with 
necrosis and hemorrhage.22 These differential devel-
opmental processes may partly explain the variable 
appearances. In the present study, the morphology of 
primary malignant ovarian tumors was likely affected 
by that of serous carcinoma, as the majority of primary 
malignant tumors were serous carcinomas. 
 Similarly, metastasis also presented variable appear-
ances in the present study. This may be due to differ-
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ences in primary sites, as reported by previous studies. 
Krukenberg tumors typically show bilateral and solid 
appearance.20, 25–27 Metastasis from colon cancer and 
appendiceal cancer often appear as multicystic ovarian 
tumors.26, 28 Hence, morphological features are not useful 
determinants for the distinction between different types 
of bilateral ovarian tumors on MR imaging. Further 
subgroup analysis of metastasis is required, although it 
was difficult in this study because of the small number.
 In the present study, we did not find any significant 
difference in ascites and peritoneal implants. These 
features were often present in both of primary malignant 
ovarian tumors and metastasis. Our results on the rele-
vance of ascites is in agreement with a previous study.7 
Serous carcinoma, in particular HGSC, often appears 
as massive ascites and peritoneal implants.29 Peritoneal 
implants are more frequently present in serous carcino-
ma compared to other histological subtypes of ovarian 
cancers.21 Therefore, most patient cases of primary 
ovarian tumors presented ascites and peritoneal implants 
because the majority were serous carcinoma. On the 
other hand, ascites and peritoneal implants are also com-
mon features in carcinomatous peritonitis, and advanced 
stage cancer patients with metastatic ovarian tumors of-
ten present carcinomatous peritonitis. Peritoneal spread 
is considered one of the underlying causes of ovarian 
metastasis from the primary site.4 Therefore, most 
patients with metastasis presented ascites and peritoneal 
implants. 
 Previous studies reported that useful factors to 
differentiate primary from metastatic ovarian tumors 
Table 3. MR findings of primary malignant ovarian tumors and metastasis
N Morphology (n) Ascites (n) Peritoneal implant (n)
Solid Cystic ++ + − + −
Primary malignant ovarian tumors 42 23 19 21 14 7 37 5
Serous carcinoma 36 21 15 19 11 6 34 2
Clear cell carcinoma 3 1 2 2 0 1 2 1
Carcinosarcoma 2 1 1 0 2 0 1 1
Endometrioid borderline tumor/carcinoma 1 0 1 0 1 0 0 1
Metastasis 12 5 7 8 4 0 9 3
Appendiceal cancer 3 1 2 3 0 0 2 1
Cervical cancer 2 1 1 1 1 0 2 0
Colon cancer 2 1 1 0 2 0 2 0
Bile duct cancer 1 0 1 1 0 0 1 0
Gastric cancer 1 1 0 1 0 0 1 0
Kidney cancer 1 0 1 1 0 0 0 1
Peritoneal mesothelioma 1 0 1 1 0 0 1 0
Malignant lymphoma 1 1 0 0 1 0 0 1
Ascites+: not beyond the pelvic cavity; Ascites++: beyond the pelvic cavity 
MR, magnetic resonance.
were age, multilocularity, uniformity of locules and 
enhancement patterns of solid component.7, 8 Ovarian 
tumors, particularly serous carcinomas show complex 
appearances and have various micro cysts with col-
lapsed morphology and mixture of necrosis and solid 
component. Thus, it is difficult to precisely evaluate the 
multilocularity and uniformity of locules. We also did 
not evaluate enhancement pattern and apparent diffusion 
coefficient (ADC) values because distinct MR devices 
were used for patient examination. 
 The present study has a number of limitations. First, 
several distinct MR devices were used. Second, the 
study population was small, in particular metastasis and 
primary malignant ovarian tumors except serous car-
cinoma. Further investigations are required to validate 
the present results in a larger population cohort. Third, 
the patients diagnosed with serous carcinoma in the 
present study may include both ovarian and peritoneal 
carcinoma, because based on the recent study about se-
rous tubal intraepithelial carcinoma (STIC) theory, it is 
said that there is no longer a reason for classifying high-
grade serous carcinoma into ovarian, tubal, or peritoneal 
origin30. Fourth, we did not evaluate endometriotic cysts. 
We classified ovarian tumors in reference to the World 
Health Organization (WHO) histological classification 
of tumors of the ovary (2003),31 in which endometriotic 
cysts are not classified as ovarian tumors. Fifth, while 
ovarian tumor-like lesions were not included in the pres-
ent study, it is important to note that some tumor-like 
lesions such as hyperreactio luteinalis, fibromatosis and 
stromal hyperplasia sometimes demonstrate bilateral 
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4th ed. Lyon: IARC press; 2014.
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J Surg Pathol. 2010;34:433-43. PMID: 20154587.
24 Lalwani N, Prasad SR, Vikram R, Shanbhogue AK, Huettner 
PC, Fasih N. Histologic, molecular, and cytogenetic features 
of ovarian cancers: implications for diagnosis and treatment. 
Radiographics. 2011;31:625-46. PMID: 21571648.
25 Ha HK, Baek SY, Kim SH, Kim HH, Chung EC, Yeon KM. 
Krukenberg’s tumor of the ovary: MR imaging features. AJR. 
1995;164:1435-9. PMID: 7754887.
26 Choi HJ, Lee J-H, Kang S, Seo S-S, Choi J-I, Lee S, et 
al. Contrast-Enhanced CT for Differentiation of Ovarian 
Metastasis from Gastrointestinal Tract Cancer: Stomach 
Cancer Versus Colon Cancer. AJR. 2006;187:741-5. PMID: 
16928939.
27 Koyama T, Mikami Y, Saga T, Tamai K, Togashi K. 
Secondary ovarian tumors: spectrum of CT and MR features 
with pathologic correlation. Abdom Imaging. 2007;32:784-95. 
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28 Willmott F, Allouni KA, Rockall A. Radiological manifesta-
tions of metastasis to the ovary. J Clin Pathol. 2012;65:585-90. 
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ovarian lesions. Sixth, CA 125 serum level of metastasis 
is affected by primary site. The cancers of liver, pancre-
as and bile ducts are known to show high CA 125 level. 
If metastases from these primary sites are collected, a 
different result might be derived.
 In conclusion, in the present study, most bilateral 
ovarian tumors on MR imaging were defined as serous 
carcinoma, mature teratoma or metastasis. CA 125 
serum level and maximum tumor diameter are useful 
indicators for the differentiation between metastasis and 
serous carcinoma or primary malignant ovarian tumors.
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